Switch theme
Sign up to access all valuation multiples
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.
2018
5
Last FY Revenue $1.1M
Last FY EBITDA -$0.8M
$0.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, DanCann Pharma achieved revenue of $1.1M and an EBITDA of -$0.8M.
DanCann Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See DanCann Pharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.1M | XXX | XXX | XXX |
| Gross Profit | XXX | -$0.1M | XXX | XXX | XXX |
| Gross Margin | XXX | -5% | XXX | XXX | XXX |
| EBITDA | XXX | -$0.8M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -67% | XXX | XXX | XXX |
| EBIT | XXX | -$1.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -96% | XXX | XXX | XXX |
| Net Profit | XXX | -$1.3M | XXX | XXX | XXX |
| Net Margin | XXX | -113% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, DanCann Pharma's stock price is DKK 1 (or $0).
DanCann Pharma has current market cap of DKK 5.3M (or $0.8M), and EV of DKK 1.8M (or $0.3M).
See DanCann Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $0.3M | $0.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, DanCann Pharma has market cap of $0.8M and EV of $0.3M.
DanCann Pharma's trades at 0.2x EV/Revenue multiple, and -0.4x EV/EBITDA.
Equity research analysts estimate DanCann Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
DanCann Pharma's P/E ratio is not available.
See valuation multiples for DanCann Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $0.8M | XXX | $0.8M | XXX | XXX | XXX |
| EV (current) | $0.3M | XXX | $0.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -0.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDanCann Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
DanCann Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
DanCann Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for DanCann Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -67% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 92% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DanCann Pharma acquired XXX companies to date.
Last acquisition by DanCann Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . DanCann Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was DanCann Pharma founded? | DanCann Pharma was founded in 2018. |
| Where is DanCann Pharma headquartered? | DanCann Pharma is headquartered in Sweden. |
| How many employees does DanCann Pharma have? | As of today, DanCann Pharma has 5 employees. |
| Is DanCann Pharma publicy listed? | Yes, DanCann Pharma is a public company listed on SAT. |
| What is the stock symbol of DanCann Pharma? | DanCann Pharma trades under DANCAN ticker. |
| When did DanCann Pharma go public? | DanCann Pharma went public in 2020. |
| Who are competitors of DanCann Pharma? | Similar companies to DanCann Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of DanCann Pharma? | DanCann Pharma's current market cap is $0.8M |
| Is DanCann Pharma profitable? | Yes, DanCann Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
